Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

msh id	COM:TEVAPHARM
symbol	TEVA
name	Teva Pharmaceutical Industries Limited
homepage url	https://www.tevapharm.com
country	IL
sector	Healthcare
industry	Drug Manufacturers - Specialty & Generic
market	STOCKS
employee count	35K
crunchbase url	-
linkedin url	-
founders	-

market cap	19.23B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.03
growth cost of revenue	0.03
growth depreciation and amortization	-1
growth ebitda	-0.89
growth ebitda ratio	-0.9
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.02
growth gross profit	0.1
growth gross profit ratio	0.03

COM:TEVAPHARM

Teva Pharmaceutical Industries Ltd.

Last Close

17.03

21/11 19:30

Market Cap

19.23B

Beta: -

Volume Today

3.40M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	12.65B
cost of revenue	12.65B
depreciation and amortization	-
ebitda	433M
ebitda ratio	0.03
eps	-0.5
eps diluted	-0.49
operating expenses	4.45B
operating income	433M
operating income ratio	0.03

accounts receivables	12M
capital expenditure	-526M
cash at beginning of period	2.83B
cash at end of period	3.23B
inventory	4.02B
working capital ttm	238M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-